May 4, 2010 (Barcelona, Spain) — Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, ...

In a recent study published in Scientific Reports, a group of researchers investigated the differences in prostate magnetic resonance imaging (MRI) findings and clinical characteristics between ...

A key gene that fuels the molecular cascade driving prostate cancer bone metastasis progression may open avenues for targeted therapies. With this mda-9 mice model, Fisher and his team observed how ...

Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

B ERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy ...

Early data show promising results for cabozantinib, a new therapeutic agent for castration-resistant prostate cancer (CRPC), particularly against tumors that have metastasized to the bone. In a phase ...

Weill Cornell Medicine received a $1.5 million grant from the U.S. Department of Defense Prostate Cancer Research Program to develop new approaches for predicting the spread of cancer cells to the ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

New research from scientists at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) determined that a particular gene is the ringleader behind a molecular domino ...